PDTIParticle Drilling Technologies, Inc. (Houston, TX)
PDTIPet Dog Training Instructors (est. 2005)
PDTIPowell Duffryn Terminals, Inc. (various locations)
PDTIPulsed Doppler Tissue Imaging
References in periodicals archive ?
2, inciso XXII o PDTI e um instrumento de diagnostico, planejamento e gestao dos recursos e processos de TI de um orgao para um determinado periodo.
Further, PDTI is a development stage company that operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond PDTI's control such as announcements by competitors and service providers.
In connection with this sale, PDTI entered into a registration rights agreement with the investors requiring, among other things, that PDTI register the resale of the shares.
the chief executive officer of PDTI, stated: "This merger continues to advance the Particle Drilling business plan as we remain focused on final development and commercialization of our technology.
With these management changes, PDTI believes it has an outstanding team of energy professionals in place to complete the commercialization of its PID technology.
During the quarter, PDTI commenced a 401(k)-Employee Stock Ownership Plan (ESOP) to accommodate employee investment interest in PDTI stock.
Overall, PDTI has initiated 15 clinical studies, in 4 disease areas, at 44 sites worldwide.
In addition to its programs in cancer, PDTI is pursuing applications for photodynamic therapy in a number of medical specialties, including oncology, urology, dermatology, ophthalmology, cardiology and gynecology.
The recommendation indicates that PDTI is in compliance with the most stringent general manufacturing standard and medical device quality standard for manufacturers selling products in Europe.
In the third quarter, PDTI was pleased to announce an agreement with Pharmacia & Upjohn for the co-development of the company's photodynamic therapy for treating diseases of the eye.
Pharmacia & Upjohn will reimburse PDTI for incurred ophthalmology development expenses and will fund future clinical and preclinical studies of SnET2 for treating diseases of the eye.